141 related articles for article (PubMed ID: 26630041)
1. Mesalamine Intolerance in Three Children with Crohn's Disease.
Tuna Kirsaclioglu C; Kuloglu Z; Ustundag G; Kansu A; İnce E; Ensari A; Girgin N
Med Princ Pract; 2016; 25(3):293-5. PubMed ID: 26630041
[TBL] [Abstract][Full Text] [Related]
2. Mesalazine-induced Churg-Strauss syndrome in a patient with Crohn's disease and sclerosing cholangitis.
Sinico RA; Sabadini E; Maresca AM
Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S104. PubMed ID: 16859609
[No Abstract] [Full Text] [Related]
3. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
4. Mesalamine-induced myopericarditis in a paediatric patient with Crohn's disease.
Nair AG; Cross RR
Cardiol Young; 2015 Apr; 25(4):783-6. PubMed ID: 24915235
[TBL] [Abstract][Full Text] [Related]
5. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
Modigliani R; Colombel JF; Dupas JL; Dapoigny M; Costil V; Veyrac M; Duclos B; Soulé JC; Gendre JP; Galmiche JP; Danne O; Cadiot G; Lamouliatte H; Belaïche J; Mary JY
Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877
[TBL] [Abstract][Full Text] [Related]
6. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
Bonapace CR; Mays DA
Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
[TBL] [Abstract][Full Text] [Related]
7. Mesalamine-induced myocarditis following diagnosis of Crohn's disease: a case report.
Galvão Braga C; Martins J; Arantes C; Ramos V; Vieira C; Salgado A; Magalhães S; Correia A
Rev Port Cardiol; 2013 Sep; 32(9):717-20. PubMed ID: 23993290
[TBL] [Abstract][Full Text] [Related]
8. Interstitial nephritis in children with Crohn's disease.
Benador N; Grimm P; Lemire J; Griswold W; Billman G; Reznik V
Clin Pediatr (Phila); 2000 Apr; 39(4):253-4. PubMed ID: 10791141
[No Abstract] [Full Text] [Related]
9. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
10. Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts.
Lichtenstein GR; Cuffari C; Kane SV; Hanauer S; Present DH
Inflamm Bowel Dis; 2004 Jul; 10 Suppl 2():S11-21. PubMed ID: 15475769
[No Abstract] [Full Text] [Related]
11. [Angioedema in Crohn's disease possibly due to mesalazine].
Nguyen-Khac E; Le Baron F; Thevenot T; Tiry-Lescut C; Tiry F
Gastroenterol Clin Biol; 2002 May; 26(5):535-6. PubMed ID: 12122371
[No Abstract] [Full Text] [Related]
12. Mesalamine derivatives in the treatment of Crohn's disease.
Harrell LE; Hanauer SB
Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540
[TBL] [Abstract][Full Text] [Related]
13. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
14. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial.
Prantera C; Cottone M; Pallone F; Annese V; Franzè A; Cerutti R; Bianchi Porro G
Gastroenterology; 1999 Mar; 116(3):521-6. PubMed ID: 10029609
[TBL] [Abstract][Full Text] [Related]
15. [Inflammatory diseases of the intestines].
Felley C; Guyot J; Hess J; Mottet C; Delarive J; Michetti P
Rev Med Suisse; 2006 Jan; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
[TBL] [Abstract][Full Text] [Related]
16. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
Moum B
Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
[TBL] [Abstract][Full Text] [Related]
17. Debate: should mesalamine be used in Crohn's disease?: comments and conclusions.
Kamm MA
Inflamm Bowel Dis; 2005 Jun; 11(6):616-7. PubMed ID: 15905712
[TBL] [Abstract][Full Text] [Related]
18. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.
Cammà C; Giunta M; Rosselli M; Cottone M
Gastroenterology; 1997 Nov; 113(5):1465-73. PubMed ID: 9352848
[TBL] [Abstract][Full Text] [Related]
19. Mesalazine-induced psoriasis in patients with inflammatory bowel diseases.
Di Cesare A; Fidanza R; Riitano A; Fargnoli MC; Peris K
Eur J Dermatol; 2011; 21(5):784-5. PubMed ID: 21697068
[No Abstract] [Full Text] [Related]
20. Does the initial location of Crohn's disease have an influence on the time-to-relapse in patients under maintenance treatment with oral mesalamine?
Bresci G; Parisi G; Bertoni M; Masolino P; Scatena F; Capria A
J Clin Gastroenterol; 2000 Sep; 31(2):147-51. PubMed ID: 10993432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
